Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. 2015

Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
Department of Urology, University Hospital, Tübingen, Germany; Vancouver Prostate Centre, University of British Columbia, Vancouver, Canada.

BACKGROUND Disseminated tumor cells (DTC) can be detected in a high proportion of patients with localized solid malignancies. In prostate cancer (PC), determination of DTCs is critically discussed as there are conflicting results on their prognostic value. The aim of the present study was to evaluate the presence and prognostic role of DTCs in PC patients with a high risk of disease recurrence. METHODS 248 patients with clinically localized PC undergoing radical prostatectomy with features of increased risk of recurrence (PSA ≥10 ng/ml or Gleason score ≥ 4 + 3 = 7 or pT ≥3) were included. All patients underwent intraoperative bone marrow (BM) aspiration biopsy. BM cells were evaluated by immunocytochemistry for cytokeratines and the apoptosis marker caspase-cleaved cytokeratin 18 (M30). Results of immunocytochemistry were correlated with clinical and pathological parameters and clinical outcome of the patients. RESULTS Of 248 patients, 47 (19.0%) had evidence of DTCs at time of radical prostatectomy. In 17 of these 47 patients (36.2%), DTCs expressed the apoptosis marker M30. We observed no correlation between the presence of DTCs and tumor stage, nodal stage, prostate-specific antigen, or Gleason score. After a median-follow-up of 58 months (23-76), no differences in rates of biochemical recurrence, development of metastases and cancer-specific death were observed between patients with and without DTCs while apoptosis markers had no role. CONCLUSIONS In a single-centre cohort of patients with increased risk for disease recurrence, the presence of DTCs at the time of prostatectomy does not influence clinical outcome. For the first time in patients with PC, DTCs were evaluated for immunocytological features indicating apoptosis. Due to conflicting results of studies on DTCs, BM biopsies at time of radical prostatectomy cannot be recommended as a standard procedure in patients with clinically localized PC.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011468 Prostatectomy Complete or partial surgical removal of the prostate. Three primary approaches are commonly employed: suprapubic - removal through an incision above the pubis and through the urinary bladder; retropubic - as for suprapubic but without entering the urinary bladder; and transurethral (TRANSURETHRAL RESECTION OF PROSTATE). Prostatectomy, Retropubic,Prostatectomy, Suprapubic,Prostatectomies,Prostatectomies, Retropubic,Prostatectomies, Suprapubic,Retropubic Prostatectomies,Retropubic Prostatectomy,Suprapubic Prostatectomies,Suprapubic Prostatectomy
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D016016 Proportional Hazards Models Statistical models used in survival analysis that assert that the effect of the study factors on the hazard rate in the study population is multiplicative and does not change over time. Cox Model,Cox Proportional Hazards Model,Hazard Model,Hazards Model,Hazards Models,Models, Proportional Hazards,Proportional Hazard Model,Proportional Hazards Model,Cox Models,Cox Proportional Hazards Models,Hazard Models,Proportional Hazard Models,Hazard Model, Proportional,Hazard Models, Proportional,Hazards Model, Proportional,Hazards Models, Proportional,Model, Cox,Model, Hazard,Model, Hazards,Model, Proportional Hazard,Model, Proportional Hazards,Models, Cox,Models, Hazard,Models, Hazards,Models, Proportional Hazard

Related Publications

Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
October 2019, The Prostate,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
October 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
July 2009, BJU international,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
April 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
September 2007, Der Urologe. Ausg. A,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
September 1999, Clinical cancer research : an official journal of the American Association for Cancer Research,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
June 1996, World journal of surgery,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
April 2014, Der Urologe. Ausg. A,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
August 2001, The Journal of urology,
Tilman Todenhöfer, and Jörg Hennenlotter, and Frank Faber, and Diethelm Wallwiener, and David Schilling, and Ursula Kühs, and Stefan Aufderklamm, and Simone Bier, and Johannes Mischinger, and Georgios Gakis, and Tanja Fehm, and Arnulf Stenzl, and Christian Schwentner
November 2016, Urologic oncology,
Copied contents to your clipboard!